Get the Stockscreener App
2.1492
1.18%
0.0292
Compass Therapeutics Inc stock is traded at $2.1492, with a volume of 263.98K.
It is up +1.18% in the last 24 hours and up +15.32% over the past month.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.
See More
Previous Close:
$2.12
Open:
$2.1
24h Volume:
263.98K
Relative Volume:
0.20
Market Cap:
$297.30M
Revenue:
-
Net Income/Loss:
$-45.44M
P/E Ratio:
-6.1406
EPS:
-0.35
Net Cash Flow:
$-42.28M
1W Performance:
+2.63%
1M Performance:
+15.32%
6M Performance:
+31.60%
1Y Performance:
+57.72%
1-Day Range:
$2.06
$2.165
1-Week Range:
$2.06
$2.2299
52-Week Range:
$0.765
$4.08
Compass Therapeutics Inc Stock (CMPX) Company Profile
Name
Compass Therapeutics Inc
Sector
Industry
Phone
617-500-8099
Address
80 GUEST STREET, BOSTON
Compare CMPX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CMPX
Compass Therapeutics Inc
|
2.15 | 290.39M | 0 | -45.44M | -42.28M | -0.35 |
|
ONC
Beone Medicines Ltd Adr
|
247.37 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.61 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 40.37M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.42 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
491.16 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
Compass Therapeutics Inc Stock (CMPX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-02-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Feb-24-25 | Initiated | Guggenheim | Buy |
| Feb-19-25 | Initiated | Piper Sandler | Overweight |
| Dec-23-24 | Initiated | D. Boral Capital | Buy |
| Nov-15-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Sep-16-24 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jan-31-23 | Initiated | Jefferies | Buy |
| Jan-27-23 | Initiated | Stifel | Buy |
| May-23-22 | Resumed | H.C. Wainwright | Buy |
| Mar-15-22 | Initiated | Ladenburg Thalmann | Buy |
| Jan-19-22 | Initiated | B. Riley Securities | Buy |
| Dec-22-21 | Initiated | Raymond James | Outperform |
| Dec-20-21 | Initiated | SVB Leerink | Outperform |
| Dec-15-21 | Initiated | Wedbush | Outperform |
View All
Compass Therapeutics Inc Stock (CMPX) Latest News
Northern Trust Corp Sells 43,164 Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) - Defense World
Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference - GlobeNewswire
Insider Buying: Thomas Schuetz Acquires Additional Shares of Com - GuruFocus
Compass Therapeutics CEO acquires $21,100 in common stock By Investing.com - Investing.com India
Compass Therapeutics CEO acquires $21,100 in common stock - Investing.com
Compass Therapeutics CEO Acquires 10,000 Shares - TradingView
Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Average Rating of “Buy” from Brokerages - Defense World
Dimensional Fund Advisors LP Buys New Stake in Babcock & Wilcox Enterprises, Inc. (NYSE:BW) - Defense World
Bell Investment Advisors Inc Buys 79 Shares of Apple Inc. (NASDAQ:AAPL) - Defense World
Dark Forest Capital Management LP Cuts Stock Holdings in NVIDIA Co. (NASDAQ:NVDA) - Defense World
Price T Rowe Associates Inc. MD Increases Holdings in Absci Co. (NASDAQ:ABSI) - Defense World
Compass Therapeutics, Inc. (NASDAQ:CMPX) Shares Bought by Price T Rowe Associates Inc. MD - Defense World
Heron Therapeutics, Inc. (NASDAQ:HRTX) Shares Purchased by Price T Rowe Associates Inc. MD - Defense World
Ceera Investments LLC Grows Stock Position in Apple Inc. (NASDAQ:AAPL) - Defense World
Apple Inc. (NASDAQ:AAPL) is Sound View Wealth Advisors Group LLC’s Largest Position - Defense World
Frontier Asset Management LLC Acquires 1,041 Shares of Apple Inc. (NASDAQ:AAPL) - Defense World
Rebalance LLC Grows Stake in Apple Inc. (NASDAQ:AAPL) - Defense World
Ocugen, Inc. (NASDAQ:OCGN) Shares Sold by Price T Rowe Associates Inc. MD - Defense World
Voya Investment Management LLC Sells 5,102 Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) - Defense World
Spotlight On Three Promising Penny Stocks In May 2025 - Yahoo Finance
Perspective Therapeutics, Inc. (NYSE:CATX) Shares Acquired by Wells Fargo & Company MN - Defense World
Wells Fargo & Company MN Acquires 13,038 Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) - Defense World
Compass Therapeutics: A Big Positive Signal For Tovecimig In Biliary Tract Cancers - Seeking Alpha
Guggenheim Cuts Compass Therapeutics (NASDAQ:CMPX) Price Target to $10.00 - Defense World
Barclays PLC Has $279,000 Stock Position in Compass Therapeutics, Inc. (NASDAQ:CMPX) - Defense World
Mariner LLC Purchases New Stake in Compass Therapeutics, Inc. (NASDAQ:CMPX) - Defense World
Guggenheim Adjusts Price Target for Compass Therapeutics (CMPX) - GuruFocus
Compass Therapeutics (CMPX) Price Target Lowered by Guggenheim | CMPX Stock News - GuruFocus
Compass Therapeutics Reports 2025 First Quarter Financial Results and Provides Corporate Update - GlobeNewswire
Compass Therapeutics Reports Q1 2025 Financial Results - TipRanks
Compass Therapeutics, Inc. SEC 10-Q Report - TradingView
Compass Therapeutics to Participate in Upcoming May Investor Events - GlobeNewswire
Renaissance Technologies LLC Grows Stock Holdings in Compass Therapeutics, Inc. (NASDAQ:CMPX) - Defense World
Cholangiocarcinoma Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - Barchart.com
Compass Therapeutics, Inc. (NASDAQ:CMPX) Short Interest Up 23.4% in April - Defense World
Was Compass Therapeutics Inc (CMPX)’s session last reading good? - uspostnews.com
JPMorgan Chase & Co. Acquires 227,864 Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) - Defense World
Compass Therapeutics Inc’s Market Journey: Closing Weak at 1.90, Down -2.06 - DWinneX
Compass Therapeutics (NASDAQ:CMPX) Given Buy Rating at D. Boral Capital - Defense World
Compass Therapeutics (CMPX) Unveils Promising Data at AACR Annua - GuruFocus
Cardiol Therapeutics announces annual shareholder meeting By Investing.com - Investing.com UK
Compass Therapeutics Presents Data on Enhanced Efficacy of CTX-471 in Combination with Tovecimig in Checkpoint-Refractory Models at the American Association for Cancer Research (AACR) Annual Meeting - GlobeNewswire
Compass Therapeutics, Inc. (NASDAQ:CMPX) Position Increased by Geode Capital Management LLC - Defense World
Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Consensus Rating of “Buy” from Analysts - Defense World
2 Penny stocks to buy in May 2025 - Finbold
It is Poised to be a Bull Market for Compass Therapeutics Inc (CMPX) - Sete News
Compass Therapeutics (NASDAQ:CMPX) Earns Buy Rating from Guggenheim - Defense World
What was Compass Therapeutics Inc (CMPX)’s performance in the last session? - uspostnews.com
Compass Therapeutics Inc’s Banking’s 100-Day Moving Average at 2.2378: Will the Stock Break Through? - investchronicle.com
Compass Therapeutics (NASDAQ:CMPX) Receives Buy Rating from HC Wainwright - Defense World
Compass Therapeutics (NASDAQ:CMPX) Given “Buy” Rating at D. Boral Capital - Defense World
Compass Therapeutics Inc Stock (CMPX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Compass Therapeutics Inc Stock (CMPX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| GORDON CARL L | Director |
Apr 09 '25 |
Sale |
1.59 |
3,571,428 |
5,678,571 |
0 |
| ORBIMED ADVISORS LLC | Director |
Apr 09 '25 |
Sale |
1.59 |
3,571,428 |
5,678,571 |
0 |
2.38%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):